Search results for "Administration"

showing 10 items of 5106 documents

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct

Temsirolimus for the treatment of mantle cell lymphoma.

2010

Although recent progress has been made in the treatment of mantle cell lymphoma (MCL) the majority of patients experience relapse and ultimately die of their disease. The translocation t(11;14) is a prerequisite for the diagnosis of MCL and results in overexpression of cyclin D1. Its protein translation is controlled by mTOR, a key element of the PI3K/Akt pathway, and mTOR constitutes an attractive therapeutic target. Temsirolimus, a specific inhibitor of mTOR, has been evaluated in two Phase II trials in patients with relapsed MCL, and promising response rates up to 40% were found. Subsequently, a randomized Phase III trial was initiated, in which superiority in remission induction and pro…

AdultMaleCombination therapyChromosomal translocationAntineoplastic AgentsLymphoma Mantle-CellPharmacologyDisease-Free SurvivalDrug Administration ScheduleCyclin D1hemic and lymphatic diseasesmedicineSecondary PreventionHumansCyclin D1PI3K/AKT/mTOR pathwayAgedAged 80 and overSirolimusClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesRemission InductionIntracellular Signaling Peptides and ProteinsHematologyMiddle Agedmedicine.diseaseTemsirolimusNon-Hodgkin's lymphomaRegimenCancer researchMantle cell lymphomaFemalebusinessmedicine.drugExpert review of hematology
researchProduct

Understanding symptoms in RYR1-Related Myopathies: A mixed-methods analysis based on participants' experience

2020

Background: In rare diseases such as ryanodine receptor 1-related myopathies (RYR1-RM), health-related quality of life (HRQoL) measures are critically important so clinicians and researchers can better understand what symptoms are most important to participants, with the ultimate goal of finding tangible solutions for them. Objectives: The main objective of this study was to characterize symptoms in individuals with RYR1-RM to inform future research. A secondary objective of this study was to analyze positive and negative sentiments regarding symptoms and treatment effects post N-acetylcysteine (NAC) administration in individuals with RYR1-RM. Methods: The study used a mixed-methods design …

AdultMaleCoping (psychology)medicine.medical_specialtyWeaknessMEDLINEPainQualitative propertyArticleHealth administrationlaw.inventionInterviews as Topic03 medical and health sciences0302 clinical medicineDouble-Blind MethodMuscular DiseasesRandomized controlled triallawAdaptation PsychologicalHumansMedicine030212 general & internal medicineChildFatigueEsportsHealth economicsbusiness.industry030503 health policy & servicesPublic healthRyanodine Receptor Calcium Release ChannelMiddle AgedAcetylcysteineSocioeconomic FactorsQuality of LifeFemaleEducació físicamedicine.symptom0305 other medical sciencebusinessClinical psychology
researchProduct

Platelet aggregation, ATP release and cytoplasmic Ca2+ movement: the effects of cloricromene.

1994

A placebo-controlled, double-blind, randomized, cross-over study was performed in 24 healthy volunteers. 12 volunteers received Cloricromene (100mg gastroresistant capsules twice a day) for 7 days, the other volunteers received identical placebo capsules. Subsequently, after a 7-day wash-out period, at day 15, each subject received the other treatment. Blood samples were taken on days 1 and 15 (1st day of each treatment) as well as on days 7 and 21 (7th day of each treatment) before the morning drug administration and 2 and 4 hours later. Platelet aggregation and ATP secretion were studied in whole blood (WB) using ADP and collagen as stimulating agents. Ca2+ fluxes were studied in aequorin…

AdultMaleCytoplasmAdolescentPlatelet Aggregationchemistry.chemical_elementAdministration OralPharmacologyCalciumPlaceboAdenosine TriphosphateDouble-Blind MethodOral administrationHumansPlateletSecretionWhole bloodCalcium metabolismCross-Over StudiesChemistryChromonarHematologyMiddle AgedCrossover studyAdenosine DiphosphateAnesthesiaCalciumFemaleCollagenPlatelet Aggregation InhibitorsThrombosis research
researchProduct

Relationship between rheological properties, in vitro release and in vivo equivalency of topical formulations of diclofenac.

2019

Determination of bioequivalence remains a challenge in generic topical drug development. To support pharmacokinetic studies, strategies to demonstrate microstructure sameness of the products being compared include in vitro evaluations, such as the comparison of rheological properties, droplet size and in vitro release rates. Nevertheless, defining the appropriate acceptance range to consider equivalence between test and reference formulation is complex. To shed more light into this issue, in vitro release and rheological properties were compared to in vivo bioequivalence data (systemic blood measurements within a clinical trial) after topical application of a single dose. Test and reference…

AdultMaleDiclofenacAdolescentAdministration TopicalPharmaceutical ScienceBiological Availability02 engineering and technologyBioequivalence030226 pharmacology & pharmacy03 medical and health sciencesYoung Adult0302 clinical medicineDiclofenacPharmacokineticsRheologyIn vivomedicineHumansMathematicsTopical drugCross-Over StudiesMiddle Aged021001 nanoscience & nanotechnologyIn vitroBioavailabilityTherapeutic EquivalencyArea Under CurveFemale0210 nano-technologyRheologyBiomedical engineeringmedicine.drugInternational journal of pharmaceutics
researchProduct

A randomized trial assessing the effectiveness of different concentrations of isotretinoin in the management of lichen planus

2004

The aim of our 10-year study was to test the effectiveness of topical therapy based on 0. 18% isotretinoin, comparing it with that most frequently used, i.e. at 0.05% concentration. Seventy patients with an established diagnosis of oral lichen planus were involved in the study. The patients were randomly divided into two groups, and the drug was administered topically at 0.05% and 0. 18% concentrations. The drug at the higher concentration, according to the same protocol, was administered to the patients who did not benefit from the therapy at the lower concentration. None of the cases of reticular lichen planus showed clinical or histological improvement. In contrast, the atrophic-erosive …

AdultMaleDrugmedicine.medical_specialtyHot TemperatureRandomizationAdministration Topicalmedicine.medical_treatmentmedia_common.quotation_subjectSensationPainoral lichen planus isotretinoinlaw.inventionRandomized controlled trialRecurrencelawOral and maxillofacial pathologyHumansMedicineIsotretinoinOral UlcerIsotretinoinAgedmedia_commonChemotherapybusiness.industrySmokingMiddle Agedmedicine.diseaseDermatologyClinical trialstomatognathic diseasesTreatment OutcomeOtorhinolaryngologyFemaleSurgeryOral lichen planusDermatologic AgentsOral SurgerybusinessFollow-Up StudiesLichen Planus Oralmedicine.drug
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

The 9-item Bergen Burnout Inventory: Factorial Validity Across Organizations and Measurements of Longitudinal Data

2013

The present study tested the factorial validity of the 9-item Bergen Burnout Inventory (BBI-9) 1) . The BBI-9 is comprised of three core dimensions: (1) exhaustion at work; (2) cynicism toward the meaning of work; and (3) sense of inadequacy at work. The study further investigated whether the three-factor structure of the BBI-9 remains the same across different organizations (group invariance) and measurement time points (time invariance). The factorial group invariance was tested using a cross-sectional design with data pertaining to managers (n=742), and employees working in a bank (n=162), an engineering office (n=236), a public sector organization divided into three service areas: admin…

AdultMaleFactorialLongitudinal studyFinancial ManagementLongitudinal dataHealth Toxicology and MutagenesisSample (statistics)BurnoutEngineeringSurveys and QuestionnairesStatisticsHumansBurnoutLongitudinal StudiesBurnout ProfessionalFactorial invariancePublic SectorFactor structurePublic Health Environmental and Occupational HealthReproducibility of ResultsFactorial validityMiddle AgedBergen Burnout InventoryConfirmatory factor analysisFactor invarianceCross-Sectional StudiesOrganization and AdministrationEducational StatusFemaleOriginal ArticleLongitudinal studyFactor Analysis StatisticalPsychologySocial psychologyIndustrial Health
researchProduct

Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.

2016

Objective The aim of the study was to assess the efficacy and safety of fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 patients with CLE, refractory to topical corticosteroids, were included. The primary endpoint of the study was the evaluation of the efficacy of FAEs after 24 weeks of treatment as assessed by the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI). Results Compared to baseline, significant improvement in the mean total RCLASI activity score and the mean RCLASI activity score for skin lesions was observed in week 12 ( p = 0.002, p = 0.002, respectively) …

AdultMaleFumaric acidmedicine.medical_specialtyColicPilot ProjectsSeverity of Illness IndexDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRheumatologyFumaratesLupus Erythematosus CutaneousMedicineHumansIn patientProspective Studies030203 arthritis & rheumatologybusiness.industryHeadacheMiddle AgedDermatologyAlternative treatmentClinical trialTreatment OutcomeFumaric Acid EsterschemistryCutaneous Lupus ErythematosusFemaleOpen labelbusinessLupus
researchProduct

Acyclovir treatment in 2 patients with benign trigeminal sensory neuropathy

2001

AdultMaleHerpesvirus 3 Humanmedicine.medical_specialtymedicine.medical_treatmentAcyclovirAdministration OralNeurological disorderAntibodies ViralAntiviral AgentsHypesthesiamedicineHumansSimplexvirusAciclovirTrigeminal nerveChemotherapybusiness.industryAcyclic nucleosideHypoesthesiamedicine.diseaseDermatologySurgeryPeripheral neuropathyOtorhinolaryngologyTrigeminal Nerve DiseasesImmunoglobulin GSensory neuropathyFemaleSurgeryOral Surgerymedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Oral and Maxillofacial Surgery
researchProduct